Pharming Group N.V. (PHAR) Form 6-K — Aug 13, 2026
Pharming Group N.V. announced the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with activated PI3K delta syndrome (APDS) aged 4 and older, following inclusion of the drug on the Japan National Health Insurance drug price list. Japan is now the first market worldwide where Joenja is commercially available for children aged 4 to 11. The launch follows approval by Japan's Ministry of Health, Labour and Welfare in March 2026 as the first treatment specifically indicated for APDS.
Key figures
- Apds prevalence
- approximately 1 to 2 people per million worldwide
- Mhlw approval date
- March 2026
- Japan approved min age years
- 4
- Median diagnostic delay years
- 7
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.